Mostafa E. Salem

Dr. Mostafa E. Salem

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2016 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
Mostafa E. SalemMostafa E. Salem
Mostafa E. Salem
Ahmed F. DarweeshAhmed F. Darweesh
Ahmed F. Darweesh
AMAhmed E. M. Mekky
Ahmed E. M. Mekky
AFAhmad M. Farag
Ahmad M. Farag
AEAhmed Elwahy
Ahmed Elwahy

1 February 2016 in Tetrahedron
Verified
Journal Article
Closed access
Mostafa E. SalemMostafa E. Salem
Mostafa E. Salem
Ahmed F. DarweeshAhmed F. Darweesh
Ahmed F. Darweesh
AFAhmad M. Farag
Ahmad M. Farag
AEAhmed H.M. Elwahy
Ahmed H.M. Elwahy

21 August 2025 in Carbohydrate Polymers
Verified
Journal Article
Closed access
AEAhmed M. Elgamal
Ahmed M. Elgamal
Mostafa E. SalemMostafa E. Salem
Mostafa E. Salem
AHAmira A. Hamed
Amira A. Hamed
Ismail Abdelshafy AbdelhamidIsmail Abdelshafy Abdelhamid
Ismail Abdelshafy Abdelhamid
TATayseer A. Abdallah
Tayseer A. Abdallah
MRMohamed Ragheb
Mohamed Ragheb

8 February 2021 in Arkivoc
Verified
Journal Article
Open access
Ahmed F. DarweeshAhmed F. Darweesh
Ahmed F. Darweesh
NENesma A. Abd El-Fatah
Nesma A. Abd El-Fatah
SASamir Abouel kassem Abdel-Latif
Samir Abouel kassem Abdel-Latif
Ismail Abdelshafy AbdelhamidIsmail Abdelshafy Abdelhamid
Ismail Abdelshafy Abdelhamid
AEAhmed Elwahy
Ahmed Elwahy
Mostafa E. SalemMostafa E. Salem
Mostafa E. Salem

10 June 2025 in ACS Omega
Verified
Journal Article
Open access
EFEsraa M. Fathi
Esraa M. Fathi
Mostafa E. SalemMostafa E. Salem
Mostafa E. Salem
Farid M SroorFarid M Sroor
Farid M Sroor
FMFatma G Mohamed
Fatma G Mohamed
AEAhmed H. M. Elwahy
Ahmed H. M. Elwahy
MEMarwan Emara
Marwan Emara
Chalcone compounds have demonstrated potent anticancer activities in the past few decades with few adverse consequences. Using Claisen–Schmidt condensation, two new series of bis-chalcone derivatives (5a–c and 9a–c) bearing the thiophene moiety have been designed and generated. All compound structures were examined and elucidated by spectroscopic investigations. The MTT assay, gene expression assay, cell cycle analysis, apoptosis assay, Western blotting analysis, zymographic analysis, and molecular docking were used to evaluate the anticancer efficacy of the synthesized compounds against breast, colon, and lung cancer cells. Out of the two synthesized series, four compounds (5a, 5b, 9a, and 9b) showed significant cytotoxic effects against breast (IC50 values of 7.87 ± 2.54 and 4.05 ± 0.96 μM for compounds 5a and 5b, respectively), colon (IC50 values of 18.10 ± 2.51 and 17.14 ± 0.66 μM for compounds 5a and 9a, respectively), and lung (IC50 values of 41.99 ± 7.64 and 92.42 ± 30.91 μM for compounds 5a and 9b, respectively) cancer. These compounds upregulated the proapoptotic genes and caspase-3 and -9 protein, downregulated antiapoptotic and matrix metalloproteinase 2 (MMP-2) gene, and MMP-2 and -9 enzymatic activity. Additionally, these compounds significantly increased early and late apoptosis, necrosis, and induced cell cycle arrest at the subG1 phase with a concomitant decrease in the percentage of cell fractions at G0/G1, S, and G2/M phases. Moreover, the molecular docking was carried out on caspase-3 and -9 and MMP-2 and -9. The results suggest that compounds 5a, 5b, 9a, and 9b are potential and effective anticancer drugs.

6 September 2018 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
MHMohamed Hosny
Mohamed Hosny
Mostafa E. SalemMostafa E. Salem
Mostafa E. Salem
Ahmed F. DarweeshAhmed F. Darweesh
Ahmed F. Darweesh
AEAhmed Elwahy
Ahmed Elwahy